Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.49 |
| ▸ | KDM5A | P29375 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL356606 | 0.89 | GRM5 (0.60) | GRM5KDM4EGAAKMT2ASMYD3 | |
| SCHEMBL31654067 | 0.89 | GRM5 (0.60) | GRM5KDM4EGAAKMT2ASMYD3 | |
| SCHEMBL28824301 | 0.86 | GRM5 (0.54) | GRM5KDM4EGAAKMT2ASMYD3 | |
| SCHEMBL25053100 | 0.85 | GRM5 (0.63) | GRM5KDM4EGAAKMT2ASMYD3 | |
| SCHEMBL10827577 | 0.84 | GRM5 (0.58) | GRM5KDM4EGAAKMT2ASMYD3 | |
| SCHEMBL20147957 | 0.83 | GRM5 (0.53) | GRM5KDM4EGAAKMT2ASMYD3 | |
| SCHEMBL2241357 | 0.82 | GRM5 (0.77) | GRM5KDM4EGAAKMT2ASMYD3 | |
| SCHEMBL27314306 | 0.82 | GRM5 (0.50) | GRM5KDM4EGAAKMT2ASMYD3 | |
| SCHEMBL31091772 | 0.82 | GRM5 (0.50) | GRM5KDM4EGAAKMT2ASMYD3 | |
| SCHEMBL30338601 | 0.81 | P2RX7 (0.51) | GRM5KDM4EGAAKMT2ANTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112533904-B | Melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof | 克林提克斯医药股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| US-20250213555-A1 | SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-07-03 | — | — | US | disclosed |
| US-20240132492-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | JINAN UNIVERSITY (CN) | 2024-04-25 | — | — | US | disclosed |
| CN-115348963-B | Pyridopyrimidine compound and application thereof | 暨南大学 | 2024-04-19 | — | — | CN | disclosed |
| EP-4310084-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | Jinan University (CN) | 2024-01-24 | — | — | EP | disclosed |
| CN-115348963-A | Pyridopyrimidine compound and application thereof | 暨南大学 | 2022-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132492-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | AKT3, AKT1S1, AKT2 | GRM5 3189/4885KDM4E 1359/4885GAA 1938/4885 |
| US-20250213555-A1 | SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN1A, TRPA1 | GRM5 404/4885KDM4E 3277/4885GAA 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.